ORGO
Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis\'s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.
Organogenesis Holdings Inc. (ORGO) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Momentum (D-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | B- (3.0) | C (2.4) | B- (3.0) | D- (1.0) | C+ (2.6) | C (2.4) |
| 2026-11-07 | B- (3.0) | C+ (2.6) | B (3.5) | D- (1.0) | C+ (2.7) | C+ (2.6) |
| 2026-10-31 | B- (3.0) | C+ (2.6) | B (3.2) | D- (0.8) | C+ (2.7) | C (2.5) |
| 2026-10-24 | B- (3.0) | C+ (2.6) | B (3.2) | D- (0.9) | C+ (2.6) | C (2.5) |
| 2026-10-17 | B- (3.0) | C+ (2.6) | B (3.2) | D- (0.8) | C+ (2.6) | C (2.5) |